Ghaith Sharaf Dabbagh1, Frank Bogun2,3. 1. Division of Cardiovascular Medicine, University of Michigan Ann Arbor, Ann Arbor, MI, USA. 2. Division of Cardiovascular Medicine, University of Michigan Ann Arbor, Ann Arbor, MI, USA. fbogun@med.umich.edu. 3. Cardiovascular Center, SPC 5853, 1500 E. Medical Center Dr, Ann Arbor, MI, 48109-5853, USA. fbogun@med.umich.edu.
Abstract
PURPOSE OF REVIEW: The aim of this review is to describe predictors and therapeutic principles for PVC-induced cardiomyopathy. RECENT FINDINGS: PVC-induced cardiomyopathy is a treatable condition resulting in a reversible form of cardiomyopathy. PVC-induced cardiomyopathy has only recently been recognized as an entity that causes a reversible form of cardiomyopathy. The mechanism of development of PVC-induced cardiomyopathy has not yet been elucidated, although dyssynchrony appears to play a major role. Multiple factors have been described that are independently associated with PVC-induced cardiomyopathy. Predictors of PVC-induced cardiomyopathy include PVC prevalence, epicardial origin, male gender, longer symptom duration and asymptomatic status, presence of interpolated PVCs, lack of circadian variability, and a broader PVC-QRS width. In the presence of cardiomyopathy, work-up for structural heart disease and its etiology should be performed, followed by aggressive attempts at PVC reduction. There is evidence that ablation therapy is superior to medical therapy for frequent PVCs, but treatment decisions need to be individualized depending on the patients symptoms, PVC prevalence, PVC origin, patients comorbidities, and patient preference. The potential of sudden cardiac death associated with the presence of structural heart disease needs to be recognized, and appropriate risk stratification is mandatory.
PURPOSE OF REVIEW: The aim of this review is to describe predictors and therapeutic principles for PVC-induced cardiomyopathy. RECENT FINDINGS: PVC-induced cardiomyopathy is a treatable condition resulting in a reversible form of cardiomyopathy. PVC-induced cardiomyopathy has only recently been recognized as an entity that causes a reversible form of cardiomyopathy. The mechanism of development of PVC-induced cardiomyopathy has not yet been elucidated, although dyssynchrony appears to play a major role. Multiple factors have been described that are independently associated with PVC-induced cardiomyopathy. Predictors of PVC-induced cardiomyopathy include PVC prevalence, epicardial origin, male gender, longer symptom duration and asymptomatic status, presence of interpolated PVCs, lack of circadian variability, and a broader PVC-QRS width. In the presence of cardiomyopathy, work-up for structural heart disease and its etiology should be performed, followed by aggressive attempts at PVC reduction. There is evidence that ablation therapy is superior to medical therapy for frequent PVCs, but treatment decisions need to be individualized depending on the patients symptoms, PVC prevalence, PVC origin, patients comorbidities, and patient preference. The potential of sudden cardiac death associated with the presence of structural heart disease needs to be recognized, and appropriate risk stratification is mandatory.
Authors: Marc W Deyell; Kyoung-Min Park; Yuchi Han; David S Frankel; Sanjay Dixit; Joshua M Cooper; Mathew D Hutchinson; David Lin; Fermin Garcia; Rupa Bala; Michael P Riley; Edward Gerstenfeld; David J Callans; Francis E Marchlinski Journal: Heart Rhythm Date: 2012-05-26 Impact factor: 6.343
Authors: Miki Yokokawa; Hyungjin Myra Kim; Eric Good; Aman Chugh; Frank Pelosi; Craig Alguire; William Armstrong; Thomas Crawford; Krit Jongnarangsin; Hakan Oral; Fred Morady; Frank Bogun Journal: Heart Rhythm Date: 2011-08-17 Impact factor: 6.343
Authors: Jean-Francois Sarrazin; Troy Labounty; Michael Kuhne; Thomas Crawford; William F Armstrong; Benoit Desjardins; Eric Good; Krit Jongnarangsin; Aman Chugh; Hakan Oral; Frank Pelosi; Fred Morady; Frank Bogun Journal: Heart Rhythm Date: 2009-08-05 Impact factor: 6.343
Authors: S N Singh; R D Fletcher; S G Fisher; B N Singh; H D Lewis; P C Deedwania; B M Massie; C Colling; D Lazzeri Journal: N Engl J Med Date: 1995-07-13 Impact factor: 91.245
Authors: Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq Journal: Europace Date: 2020-08-01 Impact factor: 5.214